BI-1361849 is a mRNA Vaccine owned by Boehringer Ingelheim International, and is involved in 1 clinical trial, which was completed.

BI-1361849 (CV-9202) is a mRNA-derived lung cancer therapeutic that containing six modified mRNAs, which encode six different NSCLC associated antigens, with potential antitumor and immunomodulatory activities. Upon intradermal administration, BI-1361849 stimulates the immune system to mount both humoral and cellular responses against NSCLC cells.

The revenue for BI-1361849 is expected to reach a total of $373m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the BI-1361849 NPV Report.

BI-1361849 was originated by Curevac and is currently owned by Boehringer Ingelheim International. Curevac is the other company associated in development or marketing of BI-1361849.

BI-1361849 Overview

BI-1361849 (CV-9202) is under development for the treatment of non-small cell lung cancer in combination with radiation therapy and afatinib. It is administered intradermally. It is a RNActive-derived mRNA (messengerRNA) therapeutic comprising of six RNActive-derived molecules coding for 6 different NSCLC associated antigens, MAGE-C1, MAGE-C2, NY-ESO-1, survivin, 5T4 and Muc1. It is developed based on the RNActive technology. It was under development for the treatment of non-small cell lung cancer as a first line therapy.

Curevac Overview

Curevac is a clinical-stage biopharmaceutical company that develops RNA-based medicines. The company develops, designs, and produces messenger rna molecules for therapeutic and prophylactic vaccines in the fields of oncology and infectious diseases. Its product pipeline includes Cv0501, Cv2cov, Flu Sv Mrna and Cvsqiv. Curevac mrna-based prophylactic vaccines candidates comprise cv7202 and cv8102. it also carries out the research and development. The company Cv8102, a lead oncology candidate is designed to modulate the tumor microenvironment. Its products are used in the treatment of prostate cancer and non-small cell lung cancer, and infectious diseases such as rabies, rotavirus, influenza, and other undisclosed. Curevac is headquartered in Tubingen, Baden-Wurttemberg, Germany.

The company reported revenues of (Euro) EUR103 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of EUR48.9 million in FY2020. The operating loss of the company was EUR412.3 million in FY2021, compared to an operating loss of EUR109.8 million in FY2020. The net loss of the company was EUR411.7 million in FY2021, compared to a net loss of EUR129.1 million in FY2020. The company reported revenues of EUR11.2 million for the third quarter ended September 2022, a decrease of 44.3% over the previous quarter.

Quick View – BI-1361849

Report Segments
  • Innovator
Drug Name
  • BI-1361849
Administration Pathway
  • Intradermal
Therapeutic Areas
  • Oncology
Key Companies
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.